Rodrigo Bueno de Oliveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rodrigo Bueno de Oliveira has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Vanda Jorgetti
Universidade de São Paulo, Brazil
14 shared publications - Aluizio Barbosa Carvalho
Universidade Federal de São Paulo, Brazil
10 shared publications - Cinthia Esbrile Moraes Carbonara
Universidade Estadual de Campinas, Brazil; Universidade Estadual de Campinas, Brazil
9 shared publications - Andrei Carvalho Sposito
Department of Internal Medicine, School of Medical Sciences, State University of Campinas, Campinas, Brazil
8 shared publications - Noemi Angelica Vieira Roza
Universidade Estadual de Campinas, Brazil; Universidade Estadual de Campinas, Brazil
8 shared publications - Luciene Machado dos Reis
Universidade de São Paulo, Brazil
7 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7903
Micro- and Nanoplastics in the Human Exposome: Environmental Pathways, Kidney Toxicity, and Implications for Public Health Risk Assessment
Plastic pollution has emerged as a global environmental and public health crisis, with micro- and nanoplastics (MNPs) representing a pervasive component of the human exposome. Generated through the continuous fragmentation of larger plastic materials, MNPs exhibit physicochemical properties that influence their environmental fate, biological interactions, and toxic potential. Human exposure occurs primarily through ingestion and inhalation, facilitating particle translocation across biological barriers and systemic distribution. Experimental studies have shown that MNP exposure can disrupt mitochondrial and lysosomal function, induce oxidative stress and DNA damage, and modulate inflammatory, apoptotic, and fibrotic pathways. Although evidence supports their multiorgan toxicity, the kidney has emerged as a critical target organ due to its role in filtration and excretion. Experimental studies, often conducted at concentrations exceeding estimated environmentally relevant exposure levels, have associated renal MNP exposure with oxidative injury, apoptosis, and fibrotic remodeling, while emerging mechanistic findings suggest potential links to pro-oncogenic cellular alterations; however, these effects have not been established in humans, and their clinical relevance remains uncertain. Furthermore, the detection of plastic particles in human blood, tissues, and urine underscores the translational relevance of MNP exposure while highlighting important gaps in exposure assessment, dose–response characterization, and mechanistic understanding. In this narrative review, we integrate current evidence regarding environmental exposure pathways, biodistribution, and molecular mechanisms of MNP-induced toxicity, emphasizing the need for integrated exposome-based approaches, omics technologies, advanced experimental models, and longitudinal studies to improve human health risk assessment and guide regulatory policies.
- 4 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7903
Open AccessMicro- and Nanoplastics in the Human Exposome: Environmental Pathways, Kidney Toxicity, and Implications for Public Health Risk Assessment
Plastic pollution has emerged as a global environmental and public health crisis, with micro- and nanoplastics (MNPs) representing a pervasive component of the human exposome. Generated through the continuous fragmentation of larger plastic materials, MNPs exhibit physicochemical properties that influence their environmental fate, biological interactions, and toxic potential. Human exposure occurs primarily through ingestion and inhalation, facilitating particle translocation across biological barriers and systemic distribution. Experimental studies have shown that MNP exposure can disrupt mitochondrial and lysosomal function, induce oxidative stress and DNA damage, and modulate inflammatory, apoptotic, and fibrotic pathways. Although evidence supports their multiorgan toxicity, the kidney has emerged as a critical target organ due to its role in filtration and excretion. Experimental studies, often conducted at concentrations exceeding estimated environmentally relevant exposure levels, have associated renal MNP exposure with oxidative injury, apoptosis, and fibrotic remodeling, while emerging mechanistic findings suggest potential links to pro-oncogenic cellular alterations; however, these effects have not been established in humans, and their clinical relevance remains uncertain. Furthermore, the detection of plastic particles in human blood, tissues, and urine underscores the translational relevance of MNP exposure while highlighting important gaps in exposure assessment, dose–response characterization, and mechanistic understanding. In this narrative review, we integrate current evidence regarding environmental exposure pathways, biodistribution, and molecular mechanisms of MNP-induced toxicity, emphasizing the need for integrated exposome-based approaches, omics technologies, advanced experimental models, and longitudinal studies to improve human health risk assessment and guide regulatory policies.
- Open Access
- 14 August 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117 (1) , 130
Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis
The effects of gliflozins on bones of CKD patients on dialysis are unknown. Recently, SGLT2 expression in bone tissue of patients with CKD has been reported. We hypothesized that dapagliflozin may act in bone cells and modulate the Klotho-FGF23 axis. This study analyzed the effects of dapagliflozin on serum bone biomarkers and related outcomes. In this predefined post-hoc analysis of a previous RCT, patients on dialysis received (1:1) dapagliflozin 10 mg daily or standard care for 24 weeks. The primary endpoint was the change from baseline in serum Klotho and FGF23 levels, compared by ranked analysis of covariance, adjusted by baseline. Exploratory analyses evaluated calcium, phosphate, PTH, bone-ALP, TRAP-5b, DKK1, sclerostin, and bone proteins. Bone fractures, osteopenia, and osteoporosis were outcomes of interest. Seventy-nine patients were included in this analysis (Control N=40 and Dapagliflozin N=39). At baseline, no significant differences in biomarkers were observed. The prevalence of osteopenia and osteoporosis was 73% and 43% ( p = 0.60 and p = 1.00), respectively. After 24 weeks, the between-group analysis of the change from baseline (delta), adjusted by baseline, revealed a significant difference in serum Klotho [19.1 (− 38.9–86.3) pg/mL, Control group; − 29.1 (− 94.1–43.9) pg/mL, Dapagliflozin group (F:4.946, p = 0.03)], but not on FGF23 levels, nor other biomarkers. The follow-up prevalences of osteopenia and osteoporosis were 70% and 48% ( p = 0.27 and p = 0.61, respectively). No bone fractures were observed. Dapagliflozin use over 24 weeks in patients on dialysis was independently associated with lowered serum Klotho levels, without effects in other bone biomarkers or related outcomes.
- 14 August 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117 (1) , 130
Open AccessEffects of Dapagliflozin on the Bone of Patients with CKD on Dialysis
The effects of gliflozins on bones of CKD patients on dialysis are unknown. Recently, SGLT2 expression in bone tissue of patients with CKD has been reported. We hypothesized that dapagliflozin may act in bone cells and modulate the Klotho-FGF23 axis. This study analyzed the effects of dapagliflozin on serum bone biomarkers and related outcomes. In this predefined post-hoc analysis of a previous RCT, patients on dialysis received (1:1) dapagliflozin 10 mg daily or standard care for 24 weeks. The primary endpoint was the change from baseline in serum Klotho and FGF23 levels, compared by ranked analysis of covariance, adjusted by baseline. Exploratory analyses evaluated calcium, phosphate, PTH, bone-ALP, TRAP-5b, DKK1, sclerostin, and bone proteins. Bone fractures, osteopenia, and osteoporosis were outcomes of interest. Seventy-nine patients were included in this analysis (Control N=40 and Dapagliflozin N=39). At baseline, no significant differences in biomarkers were observed. The prevalence of osteopenia and osteoporosis was 73% and 43% ( p = 0.60 and p = 1.00), respectively. After 24 weeks, the between-group analysis of the change from baseline (delta), adjusted by baseline, revealed a significant difference in serum Klotho [19.1 (− 38.9–86.3) pg/mL, Control group; − 29.1 (− 94.1–43.9) pg/mL, Dapagliflozin group (F:4.946, p = 0.03)], but not on FGF23 levels, nor other biomarkers. The follow-up prevalences of osteopenia and osteoporosis were 70% and 48% ( p = 0.27 and p = 0.61, respectively). No bone fractures were observed. Dapagliflozin use over 24 weeks in patients on dialysis was independently associated with lowered serum Klotho levels, without effects in other bone biomarkers or related outcomes.
- Open Access
- 13 March 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117 (1) , 39
Bone from Healthy Individuals and Patients with CKD Expresses the Sodium-Glucose Co-transporter-2 (SGLT2)
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are used in type 2 diabetes mellitus management, reducing the risk of cardiovascular and renal complications. It has been stated that bone cells do not express the SGLT2 co-transporter; however, the establishment of a direct SGLT2 expression in bone and osteoblast-like cells would provide a significant advance in our understanding of direct SGLT2i effects on bone tissue from patients with metabolic bone diseases, such as chronic kidney disease or osteoporosis. SLC5A2 gene expression was investigated in osteoblast-like and renal HK-2 cells, and in human iliac crest bone samples from healthy individuals and patients with diverse stages of CKD from total RNA by real-time PCR. Additionally, SGLT2 protein qualitative expression was evaluated by Western blot in osteoblast-like cell lysates and by immunohistochemistry in bone samples from apparently healthy individuals and patients with CKD. Statistical significance was set at p < 0.05. SLC5A2 gene expression in osteoblast-like cells is comparable to HK-2 cells. Notably, in human bone samples, SLC5A2 was detected above threshold in both healthy individuals and patients with CKD; thus, absolute quantification of its transcript number of copies was feasible in bone samples for these conditions. SGLT2 protein was detected in osteoblast-like cells. Additionally, this protein was immunodetected in osteocytes embedded in mineralized trabecular and cortical bone samples from healthy subjects and patients with CKD. SLC5A2 gene expression and SGLT2 protein were detected in human osteoblast-like cells and bone from both healthy individuals and patients with CKD. These findings constitute an essential step toward advancing the understanding of effects, if any, of SGLT2 inhibitors on bone tissue from patients with CKD.
- 13 March 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117 (1) , 39
Open AccessBone from Healthy Individuals and Patients with CKD Expresses the Sodium-Glucose Co-transporter-2 (SGLT2)
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are used in type 2 diabetes mellitus management, reducing the risk of cardiovascular and renal complications. It has been stated that bone cells do not express the SGLT2 co-transporter; however, the establishment of a direct SGLT2 expression in bone and osteoblast-like cells would provide a significant advance in our understanding of direct SGLT2i effects on bone tissue from patients with metabolic bone diseases, such as chronic kidney disease or osteoporosis. SLC5A2 gene expression was investigated in osteoblast-like and renal HK-2 cells, and in human iliac crest bone samples from healthy individuals and patients with diverse stages of CKD from total RNA by real-time PCR. Additionally, SGLT2 protein qualitative expression was evaluated by Western blot in osteoblast-like cell lysates and by immunohistochemistry in bone samples from apparently healthy individuals and patients with CKD. Statistical significance was set at p < 0.05. SLC5A2 gene expression in osteoblast-like cells is comparable to HK-2 cells. Notably, in human bone samples, SLC5A2 was detected above threshold in both healthy individuals and patients with CKD; thus, absolute quantification of its transcript number of copies was feasible in bone samples for these conditions. SGLT2 protein was detected in osteoblast-like cells. Additionally, this protein was immunodetected in osteocytes embedded in mineralized trabecular and cortical bone samples from healthy subjects and patients with CKD. SLC5A2 gene expression and SGLT2 protein were detected in human osteoblast-like cells and bone from both healthy individuals and patients with CKD. These findings constitute an essential step toward advancing the understanding of effects, if any, of SGLT2 inhibitors on bone tissue from patients with CKD.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Microplásticos e diálise: um novo desafio para a nefrologia verde
RESUMO A nefrologia verde emergiu como uma estratégia fundamental para mitigar os impactos ambientais relacionados ao tratamento dos rins. Nesse contexto, a redução dos resíduos plásticos e a redução da pegada de carbono estão intimamente interligadas, uma vez que ambas visam minimizar o consumo desnecessário de recursos e a carga ambiental associada à assistência à saúde. O rápido crescimento da produção e do uso de plásticos levou à disseminação da poluição ambiental e à geração de enormes quantidades de micro e nanoplásticos (MNPs) por meio da degradação de materiais plásticos. Evidências crescentes sugerem que a exposição aos MNPs pode representar riscos potenciais à saúde humana. No entanto, importantes questões permanecem sem resposta sobre a relação entre a doença renal crônica (DRC), as terapias dialíticas e a exposição aos MNPs. Em particular, a magnitude dessa exposição, o potencial de acúmulo em pacientes com função renal comprometida e as possíveis consequências clínicas ainda são amplamente desconhecidos. Neste artigo de opinião, discutimos os desafios emergentes e as potenciais oportunidades na interface entre microplásticos, diálise e nefrologia verde.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Open AccessMicroplásticos e diálise: um novo desafio para a nefrologia verde
RESUMO A nefrologia verde emergiu como uma estratégia fundamental para mitigar os impactos ambientais relacionados ao tratamento dos rins. Nesse contexto, a redução dos resíduos plásticos e a redução da pegada de carbono estão intimamente interligadas, uma vez que ambas visam minimizar o consumo desnecessário de recursos e a carga ambiental associada à assistência à saúde. O rápido crescimento da produção e do uso de plásticos levou à disseminação da poluição ambiental e à geração de enormes quantidades de micro e nanoplásticos (MNPs) por meio da degradação de materiais plásticos. Evidências crescentes sugerem que a exposição aos MNPs pode representar riscos potenciais à saúde humana. No entanto, importantes questões permanecem sem resposta sobre a relação entre a doença renal crônica (DRC), as terapias dialíticas e a exposição aos MNPs. Em particular, a magnitude dessa exposição, o potencial de acúmulo em pacientes com função renal comprometida e as possíveis consequências clínicas ainda são amplamente desconhecidos. Neste artigo de opinião, discutimos os desafios emergentes e as potenciais oportunidades na interface entre microplásticos, diálise e nefrologia verde.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Microplastics and dialysis: a new challenge for green nephrology
Green nephrology has emerged as a pivotal strategy to mitigate the environmental impacts of kidney care. Within this framework, reducing plastic waste and lowering the carbon footprint are closely interconnected, as both aim to minimize unnecessary resource consumption and the environmental burden associated with healthcare delivery. The rapid growth of plastic production and use has led to widespread environmental pollution and the generation of enormous quantities of micro- and nanoplastics (MNPs) through plastic degradation. Increasing evidence suggests that exposure to MNPs may pose potential risks to human health. However, important questions remain unanswered regarding chronic kidney disease (CKD), dialysis therapies, and exposure to MNPs. In particular, the magnitude of exposure, the potential for accumulation in patients with impaired renal function, and the possible clinical consequences remain largely unknown. In this opinion paper, we discuss the emerging challenges and potential opportunities at the intersection of microplastics, dialysis, and green nephrology.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Open AccessMicroplastics and dialysis: a new challenge for green nephrology
Green nephrology has emerged as a pivotal strategy to mitigate the environmental impacts of kidney care. Within this framework, reducing plastic waste and lowering the carbon footprint are closely interconnected, as both aim to minimize unnecessary resource consumption and the environmental burden associated with healthcare delivery. The rapid growth of plastic production and use has led to widespread environmental pollution and the generation of enormous quantities of micro- and nanoplastics (MNPs) through plastic degradation. Increasing evidence suggests that exposure to MNPs may pose potential risks to human health. However, important questions remain unanswered regarding chronic kidney disease (CKD), dialysis therapies, and exposure to MNPs. In particular, the magnitude of exposure, the potential for accumulation in patients with impaired renal function, and the possible clinical consequences remain largely unknown. In this opinion paper, we discuss the emerging challenges and potential opportunities at the intersection of microplastics, dialysis, and green nephrology.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (3)
Uma imagem de lesões bolhosas múltiplas em um paciente em hemodiálise
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (3)
Open AccessUma imagem de lesões bolhosas múltiplas em um paciente em hemodiálise
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (3) , e20260077
An image of multiple bullous lesions in a patient on hemodialysis
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (3) , e20260077
Open AccessAn image of multiple bullous lesions in a patient on hemodialysis
- 24 June 2025
- Published by Springer Nature in Osteoporosis International
- p. 1-19
Effects of microplastics on the bones: a comprehensive review
A growing role for the skeleton in human health and longevity emerged recently. However, knowledge regarding the effects of new risk factors, linked to modern life, for bone diseases is not documented satisfactorily. Micro- and nanoplastics (MPs) are environmental and health concerns due to their widespread detection in the human surrounding environment. This narrative review aims to critically summarize current knowledge on the effects of MPs on bone and bone marrow and to explore potential links to human bone diseases, such as osteoporosis. Worryingly, MPs were recently detected in human bone tissue. In the last years, in vitro studies have shown that MPs affect cell viability, induce cell senescence, alter adipogenic cell differentiation, modify gene expression, increase reactive oxygen species production, trigger inflammatory responses, and promote osteoclastogenesis. MPs have also been associated with the impairment of the bone marrow mesenchymal stromal cell differentiation potential. Experimental animal studies indicated that MPs ingestion disturbs gut microbiota and reduces white blood cell counts, suggesting compromised bone marrow function. MPs have been detected in bone tissue following intragastric administration and were shown to affect various blood cells. Additionally, MPs accumulation in bones reduced their growth and impaired trabecular microarchitecture likely due to the osteoblasts’ decreased osteogenic function. Although numerous in vitro and in vivo studies have described the effects of MPs on cells and bone tissue using animal models, the mechanistic impact of MPs accumulation in human bones or bone marrow remains largely unexplored.
- 24 June 2025
- Published by Springer Nature in Osteoporosis International
- p. 1-19
Effects of microplastics on the bones: a comprehensive review
A growing role for the skeleton in human health and longevity emerged recently. However, knowledge regarding the effects of new risk factors, linked to modern life, for bone diseases is not documented satisfactorily. Micro- and nanoplastics (MPs) are environmental and health concerns due to their widespread detection in the human surrounding environment. This narrative review aims to critically summarize current knowledge on the effects of MPs on bone and bone marrow and to explore potential links to human bone diseases, such as osteoporosis. Worryingly, MPs were recently detected in human bone tissue. In the last years, in vitro studies have shown that MPs affect cell viability, induce cell senescence, alter adipogenic cell differentiation, modify gene expression, increase reactive oxygen species production, trigger inflammatory responses, and promote osteoclastogenesis. MPs have also been associated with the impairment of the bone marrow mesenchymal stromal cell differentiation potential. Experimental animal studies indicated that MPs ingestion disturbs gut microbiota and reduces white blood cell counts, suggesting compromised bone marrow function. MPs have been detected in bone tissue following intragastric administration and were shown to affect various blood cells. Additionally, MPs accumulation in bones reduced their growth and impaired trabecular microarchitecture likely due to the osteoblasts’ decreased osteogenic function. Although numerous in vitro and in vivo studies have described the effects of MPs on cells and bone tissue using animal models, the mechanistic impact of MPs accumulation in human bones or bone marrow remains largely unexplored.
- Open Access
- 1 April 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (2) , e20240158
Hiperparatireoidismo secundário devido à doença renal crônica e acesso ao tratamento clínico e à paratireoidectomia no Brasil: uma pesquisa nacional
Introdução: A doença renal crônica (DRC) pode levar ao hiperparatireoidismo secundário (HPTS) e seu tratamento baseia-se no controle da hiperfosfatemia, hipocalcemia e níveis séricos de paratormônio (PTH). Apesar dos avanços no tratamento do HPTS, a falha terapêutica é frequente, e pacientes com DRC em diálise demandam paratireoidectomia (PTx).
- 1 April 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (2) , e20240158
Open AccessHiperparatireoidismo secundário devido à doença renal crônica e acesso ao tratamento clínico e à paratireoidectomia no Brasil: uma pesquisa nacional
Introdução: A doença renal crônica (DRC) pode levar ao hiperparatireoidismo secundário (HPTS) e seu tratamento baseia-se no controle da hiperfosfatemia, hipocalcemia e níveis séricos de paratormônio (PTH). Apesar dos avanços no tratamento do HPTS, a falha terapêutica é frequente, e pacientes com DRC em diálise demandam paratireoidectomia (PTx).
- Open Access
- 1 April 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (2) , e20240158
Secondary hyperparathyroidism due to chronic kidney disease and access to clinical treatment and parathyroidectomy in Brazil: a nationwide survey
Introduction: Chronic kidney disease (CKD) may lead to secondary hyperparathyroidism (SHP) and its treatment is based on the control of hyperphosphatemia, hypocalcemia, and serum parathormone hormone levels (PTH) levels. Despite the advances in SHP treatment, therapeutic failure is frequent and CKD patients on dialysis require parathyroidectomy (PTx).
- 1 April 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (2) , e20240158
Open AccessSecondary hyperparathyroidism due to chronic kidney disease and access to clinical treatment and parathyroidectomy in Brazil: a nationwide survey
Introduction: Chronic kidney disease (CKD) may lead to secondary hyperparathyroidism (SHP) and its treatment is based on the control of hyperphosphatemia, hypocalcemia, and serum parathormone hormone levels (PTH) levels. Despite the advances in SHP treatment, therapeutic failure is frequent and CKD patients on dialysis require parathyroidectomy (PTx).